EST Cathie Wood’s ARK Investment bought 147K shares of Crispr Therapeutics (CRSP) todayStay Ahead of the Market:Discover outperforming ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Bengaluru (Karnataka) [India], January 16: Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics laboratory in Bengaluru.

CRISPR screening libraries are collections of carefully designed single-guide RNAs (sgRNAs) that allow researchers to ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

Researchers in the group of Associate Professor Ninib Baryawno, Department of Women's and Children's Health, KI, have ...

US genetic medicines company Scribe, which is seeking to unlock the potential of CRISPR to transform human health, announced ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Caribou has initiated the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial designed to evaluate a single infusion of CB-010 in adult patients with LN and ERL. CB-011, a ...